InflaRx Stock

InflaRx EBIT

The EBIT of InflaRx (IFRX) as of Aug 7, 2026 is -48.26 M EUR. In the previous year, EBIT was -52.91 M EUR — a change of -8.79% (higher).

EBIT

-48.26 MEUR

YoY

-8.79%

Last updated:

In 2026, InflaRx's EBIT was -48.26 M EUR, a -8.79% increase from the -52.91 M EUR EBIT recorded in the previous year.

The InflaRx EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (undefined EUR)
Date
EBIT (undefined EUR)
Jan 1, 2024
0.00 base
Jan 1, 2025
0.00 base
Jan 1, 2026 (e)
0.00 base
Jan 1, 2027 (e)
0.00 base
Jan 1, 2028 (e)
0.00 base
Jan 1, 2029 (e)
0.00 base
Jan 1, 2030 (e)
0.00 base
Jan 1, 2031 (e)
0.00 base
YEAREBIT (undefined EUR)
2031 est -
2030 est -
2029 est -
2028 est -
2027 est -
2026 est -
2025 -
2024 -
2023 -
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
Access this data via the Eulerpool API

InflaRx Revenue

InflaRx Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
165,789.00 EUR
-52.91 M EUR
-46.06 M EUR
Jan 1, 2025
29,331.00 EUR
-48.26 M EUR
-45.63 M EUR
Jan 1, 2026 (e)
15,415.00 EUR
-3,082.00 EUR
-20.12 M EUR
Jan 1, 2027 (e)
16,112.00 EUR
-3,222.00 EUR
-27.24 M EUR
Jan 1, 2028 (e)
11,650.00 EUR
-2,329.00 EUR
-28.44 M EUR
Jan 1, 2029 (e)
129.00 M EUR
-25.80 M EUR
-11.29 M EUR
Jan 1, 2030 (e)
228.20 M EUR
-45.64 M EUR
3.87 M EUR
Jan 1, 2031 (e)
36.55 M EUR
0.00 EUR
-26.87 M EUR

InflaRx Margins

InflaRx stock margins

The InflaRx margin analysis displays the gross margin, EBIT margin, as well as the profit margin of InflaRx. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for InflaRx.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
-1,900.76 %
-31,911.40 %
-27,784.96 %
Jan 1, 2025
-24,677.94 %
-164,525.49 %
-155,582.08 %
Jan 1, 2026 (e)
-24,677.94 %
-19.99 %
-130,511.59 %
Jan 1, 2027 (e)
-24,677.94 %
-20.00 %
-169,076.45 %
Jan 1, 2028 (e)
-24,677.94 %
-19.99 %
-244,080.27 %
Jan 1, 2029 (e)
-24,677.94 %
-20.00 %
-8.75 %
Jan 1, 2030 (e)
-24,677.94 %
-20.00 %
1.70 %
Jan 1, 2031 (e)
-24,677.94 %
0.00 %
-73.50 %

InflaRx Stock analysis

What does InflaRx do? Inflarx NV is a biotech company that was founded in 2007 and is headquartered in Jena, Germany. The company's goal is to develop innovative therapies for patients suffering from severe inflammatory diseases. Inflarx focuses on the active ingredient IFX-1, which can be used for various diseases. The company collaborates closely with partners from the industry and science to advance the development of new therapies. The history of Inflarx began in 2007 when Dr. Niels C. Riedemann, the co-founder of the company, discovered IFX-1. IFX-1 is an antibody that can selectively inhibit inflammatory processes in the body. Riedemann recognized the potential of IFX-1 to form a new class of therapeutics and subsequently founded Inflarx. Initially, Inflarx focused on the development of IFX-1 for the treatment of lung inflammation. However, the company later recognized the potential of IFX-1 for other diseases, including autoimmune diseases and rare diseases. Today, the company specializes in the development and marketing of therapies for the treatment of inflammatory diseases in adults. Inflarx's business model is based on the development and marketing of therapies using IFX-1. The company collaborates closely with partners from the pharmaceutical industry and science to develop new therapies. Inflarx has filed several patents for IFX-1 and has exclusive rights to its use in certain diseases. The company operates in several divisions. The "Lung Inflammatory Diseases" division focuses on the development of therapies for the treatment of lung inflammation. The "Autoimmune Diseases" division includes the development of therapies for the treatment of autoimmune diseases such as rheumatoid arthritis and Crohn's disease. The "Rare Diseases" division focuses on the development of therapies for the treatment of rare diseases where IFX-1 can be utilized. Currently, Inflarx does not offer any products on the market. However, the company is working on the development of therapies for the treatment of inflammatory diseases in adults. IFX-1 is currently in various stages of clinical development and is being tested for different indications. Inflarx has received promising data from clinical trials and plans to bring IFX-1 to the market in the future. In summary, Inflarx NV is a biotech company specializing in the development of therapies for the treatment of inflammatory diseases. The company discovered IFX-1 as an active ingredient and continues to develop its products based on it. Inflarx collaborates closely with partners from the pharmaceutical industry and science to develop new therapies and specializes in various divisions. Although Inflarx currently does not have any products on the market, the company has received promising data from clinical trials and plans to enter the market with IFX-1 in the future. InflaRx is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing InflaRx's EBIT

InflaRx's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of InflaRx's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

InflaRx's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in InflaRx’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about InflaRx stock

EBIT of InflaRx is -48.26 M EUR in 2026.

EBIT of InflaRx changed from -52.91 M EUR to -48.26 M EUR, representing a -8.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT InflaRx since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's InflaRx historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — InflaRx

All Key Metrics — InflaRx